In the journal Cancer Immunology Research, scientists revealed that a molecule called interleukin-35 plays a role in suppressing cancer-fighting immune cells in pancreatic cancer. They also reported that their preclinical study showed that knocking out IL35 worked well alongside drugs that unleash the immune system against cancer, helping to shrink tumors. Read more . . .
A University of North Carolina Lineberger Comprehensive Cancer Center study may provide insights into how to overcome barriers to using immune-based treatments for pancreatic cancer, the third most deadly cancer in the United States.